National Medical Products Administration (NMPA)
-
China approves Lumirix for mild to moderate atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurring symptoms, with the CIC report indicating that China had more than 54 million people living with AD in 2024.
-
CanSinoBIO advances Td5cp booster candidate into key stage of NMPA review
If approved and launched, the vaccine will complement CanSinoBIO’s recently approved three-component DTaP vaccine, Tripecia® (DT3cP Infant), expanding the company’s pertussis-containing vaccine portfolio across age groups.
-
Akeso secures third NMPA approval for Ivonescimab combination in China
The latest approval expands the clinical use of ivonescimab in China and follows previous NMPA authorisations for regimens containing the molecule.
-
China’s NMPA approves Satricabtagene Autoleucel for solid tumor
The decision makes satri-cel the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication.
-
Lupin secures first China NMPA approval with Oseltamivir launch
The product will be manufactured and commercialized to support treatment and prevention needs during influenza seasons, with an emphasis on improving availability for younger patients across China.
-
GSK’s Exdensur secures NMPA approval in China for chronic rhinosinusitis
The medication works as an add-on therapy alongside intranasal corticosteroids for patients whose condition fails to respond adequately to systemic corticosteroids or surgical intervention.
-
Sciwind Biosciences gains Chinese approval for Ecnoglutide weight loss injection
The NMPA based its approval decision on Phase III clinical trial data published in The Lancet Diabetes & Endocrinology in June 2025.
-
Zai Lab secures China approval for Augtyro to treat NTRK fusion-positive solid tumors
The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.